Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.

ATI Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- PARTICIPANTS WITH ATOPIC DERMATITIS RECEIVING ATI-2138 EXPERIENCED IMPROVEMENTS IN KEY CLINICAL MEASURES INCLUDING DISEASE SEVERITY, ITCH, AND QUALITY OF LIFE - WAYNE, PA., MARCH 27, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY PROVIDED ADDITIONAL RESULTS FROM ITS PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF ITK AND JANUS KINASE 3 (JAK3), PRESENTED IN AN ELECTRONIC POSTER AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN DENVER, CO.

RESULTS PRESENTED AT 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING PROVIDE ADDITIONAL SUPPORT FOR THE THERAPEUTIC POTENTIAL OF ATI-2138

WAYNE, PA., MARCH 20, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT AN EPOSTER ON THE RESULTS FROM ITS OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF INTERLEUKIN-2-INDUCIBLE T CELL KINASE (ITK) AND JANUS KINASE 3 (JAK3), WILL BE AVAILABLE DURING THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN DENVER, CO. THE POSTER WILL INCLUDE RESULTS NOT PREVIOUSLY REPORTED FROM ACLARIS' PHASE 2A TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS ANNOUNCES POSTER ON RESULTS FROM PHASE 2A TRIAL OF ATI-2138 AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING

- TOP LINE RESULTS EXPECTED IN THE FOURTH QUARTER OF 2026 - WAYNE, PA., MARCH 18, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS COMPLETED PATIENT ENROLLMENT IN ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS

- POSITIVE INTERIM RESULTS OF PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 SUPPORT RAPID CLINICAL ADVANCEMENT; COMPLETE TOP LINE RESULTS EXPECTED IN THE SECOND QUARTER OF 2026 -  - PHASE 1B PROOF-OF-CONCEPT TRIALS OF ATI-052 IN ATOPIC DERMATITIS (AD) AND ASTHMA UNDERWAY; TOP LINE RESULTS FROM BOTH TRIALS ANTICIPATED IN THE SECOND HALF OF 2026 -  - INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR LEAD ITK INHIBITOR CANDIDATE ATI-9494 EXPECTED IN THE SECONDHALF OF 2026 -  - ATI-2138, ACLARIS' INVESTIGATIONAL INHIBITOR OF ITK AND JAK3, DEMONSTRATED POTENTIAL BEST-IN-CLASS HAIR REGROWTH IN MURINE ALOPECIA MODEL -  WAYNE, PA., FEB. 26, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED 2025 AND PROVIDED A CORPORATE UPDATE.

ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WAYNE, PA., FEB. 24, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS INITIATED A PLACEBO-CONTROLLED PHASE 1B PROOF-OF-CONCEPT (POC) TRIAL OF ATI-052, THE COMPANY'S POTENTIAL BEST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTI-TSLP/IL-4R ANTIBODY, IN ASTHMA. THIS ANNOUNCEMENT FOLLOWS THE RECENT INITIATION OF THE COMPANY'S PHASE 1B POC TRIAL OF ATI-052 IN ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4R ANTIBODY ATI-052

DALLAS, FEB. 19, 2026 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED THE ADDITIONAL REPURCHASE OF UP TO $500 MILLION OF ITS OUTSTANDING COMMON STOCK, WHICH THE COMPANY CURRENTLY EXPECTS WILL SUPPORT A MULTI-YEAR SHARE REPURCHASE PROGRAM IN COMBINATION WITH THE CURRENTLY REMAINING $120 MILLION FROM ITS PRIOR AUTHORIZATION. REPURCHASES UNDER THE PROGRAM MAY BE MADE IN THE OPEN MARKET OR IN PRIVATELY NEGOTIATED TRANSACTIONS, WITH THE AMOUNT AND TIMING OF REPURCHASES DEPENDING ON MARKET CONDITIONS AND CORPORATE NEEDS.

ATI ANNOUNCES MULTI-YEAR $500 MILLION SHARE REPURCHASE PROGRAM

ANNUAL SALES OF $4.6 BILLION REPRESENT HIGHEST TOTAL SINCE 2012 Q4 2025 SALES OF $1.2 BILLION AND FISCAL YEAR 2025 SALES OF $4.6 BILLION Q4 2025 NET INCOME ATTRIBUTABLE TO ATI OF $97 MILLION, OR $0.69 PER SHARE; FISCAL YEAR 2025 NET INCOME ATTRIBUTABLE TO ATI OF $404 MILLION, OR $2.85 PER SHARE SALES TO THE AEROSPACE & DEFENSE MARKET REPRESENT 68% OF Q4 2025 SALES, UP FROM 65% OF Q4 2024 SALES FISCAL YEAR 2025 OPERATING CASH FLOW OF $614 MILLION, UP FROM $407 MILLION FOR FISCAL YEAR 2024 NON-GAAP INFORMATION(A) Q4 2025 ADJUSTED NET INCOME ATTRIBUTABLE TO ATI(A) OF $130 MILLION, OR $0.93 PER SHARE Q4 2025 ADJUSTED EBITDA(A) OF $232 MILLION, OR 19.7% OF SALES FISCAL YEAR 2025 ADJUSTED FREE CASH FLOW(A) OF $380 MILLION, UP 53% OVER FISCAL YEAR 2024 GUIDANCE THE COMPANY IS PROVIDING FIRST QUARTER AND FISCAL YEAR 2026 GUIDANCE IN THE TABLE BELOW. CURRENT GUIDANCE Q1 2026 FISCAL YEAR 2026 ADJUSTED EBITDA(B) $216M - $226M $975M - $1,025M ADJUSTED EARNINGS PER SHARE(B) $0.83 - $0.89 $3.99 - $4.27 ADJUSTED FREE CASH FLOW(B) $430M - $490M (A) RECONCILIATIONS OF THE REPORTED INFORMATION UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES (GAAP) TO NON-GAAP FINANCIAL MEASURES ARE INCLUDED IN ACCOMPANYING FINANCIAL TABLES.

ATI ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2025 RESULTS

WAYNE, PA., JAN. 12, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS INITIATED A PLACEBO-CONTROLLED PHASE 1B PROOF-OF-CONCEPT (POC) TRIAL IN ATOPIC DERMATITIS (AD) FOR ATI-052, THE COMPANY'S POTENTIAL BEST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTI-TSLP/IL-4R ANTIBODY. WE ARE EXPERIENCING STRONG MOMENTUM IN THE ATI-052 CLINICAL DEVELOPMENT PROGRAM INCLUDING THE RECENT POSITIVE PHASE 1A INTERIM RESULTS WHICH DEMONSTRATED A STRONG SAFETY AND TOLERABILITY PROFILE, EXTENDED PHARMACOKINETICS, AND CONCENTRATION-DEPENDENT PHARMACODYNAMICS EVEN AT THE LOWEST DOSE, SAID DR. JESSE HALL, CHIEF MEDICAL OFFICER OF ACLARIS.

ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN ATOPIC DERMATITIS (AD) WITH ITS NOVEL BISPECIFIC ANTIBODY ATI-052

FRIENDSHIP, N.Y., JAN. 09, 2026 (GLOBE NEWSWIRE) -- WHAT ARE THE MOST COMMON MISTAKES PEOPLE MAKE WHEN IT COMES TO LIFE INSURANCE?

INSURANCE EXPERT MICHELLE HALL OF ALLEGHENY COUNTY OUTLINES COMMON LIFE INSURANCE MISTAKES FOR HELLONATION

- POSITIVE INTERIM RESULTS OF PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL REINFORCE POTENTIAL BEST-IN-CLASS POTENCY ADVANTAGE OF ATI-052 - - TRIAL RESULTS SUPPORT POTENTIAL FOR EXTENDED DOSING OF UP TO EVERY THREE MONTHS - - INITIATION OF PHASE 1B PROOF-OF-CONCEPT (POC) TRIALS IN ATOPIC DERMATITIS (AD) AND ASTHMA NOW EXPECTED IN FIRST QUARTER OF 2026; PLANNING UNDERWAY FOR ADVANCEMENT OF ATI-052 INTO PHASE 2B TRIAL IN AD IN THE SECOND HALF OF 2026 - - MANAGEMENT TO HOST A CONFERENCE CALL TO DISCUSS UPDATE TODAY AT 8:00 AM EST - WAYNE, PA., JAN. 06, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED POSITIVE INTERIM RESULTS FROM THE FIRST-IN-HUMAN PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ITS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052.

ACLARIS THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 1A TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 SUPPORTING EXPEDITED CLINICAL DEVELOPMENT

ATI Inc.

ATI

Price

Financial Reports

No items found.

Press Releases

ATI Inc.

ATI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ATI